Abstract
Atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are nonmalignant breast lesions that confer a 4- to 10-fold increased risk for breast cancer in women. Often, AH and LCIS are diagnosed through breast biopsy due to a mammographic or palpable finding. Although AH and LCIS are benign breast disease, further management is necessary due to their high-risk nature and premalignant potential. Over the decades, management of AH and LCIS has changed as more is learned about these disease processes. This review explores the studies evaluating the risk for breast cancer in women with AH or LCIS and the clinical management of these lesions, which can include a combination of surgical excision, surveillance, and risk-reduction therapy.
Copyright © 2018 by the National Comprehensive Cancer Network.
MeSH terms
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Biopsy / methods
-
Biopsy / standards
-
Breast / diagnostic imaging
-
Breast / pathology*
-
Breast / surgery
-
Breast Carcinoma In Situ / diagnosis
-
Breast Carcinoma In Situ / pathology
-
Breast Carcinoma In Situ / therapy*
-
Breast Neoplasms / diagnosis
-
Breast Neoplasms / pathology
-
Breast Neoplasms / prevention & control*
-
Clinical Trials as Topic
-
Female
-
Humans
-
Hyperplasia / diagnosis
-
Mammography / methods
-
Mammography / standards
-
Medical Oncology / methods
-
Medical Oncology / standards
-
Practice Guidelines as Topic
-
Prophylactic Mastectomy / methods
-
Prophylactic Mastectomy / standards
-
Risk Assessment / methods
-
Risk Assessment / standards
-
Societies, Medical / standards
-
Treatment Outcome
-
Watchful Waiting / methods
-
Watchful Waiting / standards
Substances
-
Antineoplastic Agents, Hormonal